Francisco Partners Iv, L.P. Sells 447,259 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 447,259 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68. Following the sale, the insider directly owned 913,592 shares in the company, valued at approximately $3,215,843.84. The trade was a 32.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Trading Down 3.1%

Shares of NASDAQ:GDRX traded down $0.11 during midday trading on Friday, reaching $3.45. The company’s stock had a trading volume of 1,746,243 shares, compared to its average volume of 1,833,117. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of 86.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60. The business has a 50 day moving average price of $3.13 and a 200 day moving average price of $2.63. GoodRx Holdings, Inc. has a 1 year low of $1.77 and a 1 year high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.09 earnings per share. Research analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Hedge Funds Weigh In On GoodRx

Hedge funds have recently made changes to their positions in the business. Lazard Asset Management LLC lifted its position in shares of GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after buying an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP grew its position in shares of GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after buying an additional 6,842 shares during the last quarter. Hirtle Callaghan & Co LLC grew its position in shares of GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after acquiring an additional 7,580 shares during the period. Finally, Quarry LP acquired a new stake in GoodRx during the third quarter worth about $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of recent analyst reports. TD Cowen boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Barclays upped their price target on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Thursday. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Citigroup boosted their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price objective on GoodRx in a report on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $4.23.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.